Similarly, a non-randomized, phase II clinical trial evaluated the clinical efficacy of durvalumab (anti-PD-L1 antibody) in MSI and MSS advanced or recurrent endometrial cancer, which included 35 MSI patients and 36 MSS patients, respectively, with an ORR of 47%, median PFS of 8.3 months, and OS rate of 71% at 12 months in the MSI cohort, compared with an ORR of only 3%, median PFS of 1.8 months, and 12-month OS of only 51% in the MSS cohort, which was significantly lower than the MSI cohort [26]. Here, CD274 is linked to endometrial cancer.